Innovations in Immunology
GeoVax is a clinical-stage biotechnology company developing novel therapies and vaccines for cancers and many of the world’s most threatening infectious diseases.
Our lead program in oncology is Gedeptin®, presently in a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. Our lead infectious disease program is CM04S1, a next-generation Covid-19 vaccine targeting high-risk immunocompromised patient populations, currently in two Phase 2 clinical trials.
